Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients.

López-Gómez C, Pino-Ángeles A, Órpez-Zafra T, Pinto-Medel MJ, Oliver-Martos B, Ortega-Pinazo J, Arnáiz C, Guijarro-Castro C, Varadé J, Álvarez-Lafuente R, Urcelay E, Sánchez-Jiménez F, Fernández Ó, Leyva L.

PLoS One. 2013 Apr 29;8(4):e62540. doi: 10.1371/journal.pone.0062540. Print 2013.

2.

TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response.

López-Gómez C, Oliver-Martos B, Pinto-Medel MJ, Suardiaz M, Reyes-Garrido V, Urbaneja P, Fernández Ó, Leyva L.

J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):130-7. doi: 10.1136/jnnp-2014-309932. Epub 2015 Mar 3.

3.

TRAIL/TRAIL receptor system and susceptibility to multiple sclerosis.

López-Gómez C, Fernández O, García-León JA, Pinto-Medel MJ, Oliver-Martos B, Ortega-Pinazo J, Suardíaz M, García-Trujillo L, Guijarro-Castro C, Benito-León J, Prat I, Varadé J, Álvarez-Lafuente R, Urcelay E, Leyva L.

PLoS One. 2011;6(7):e21766. doi: 10.1371/journal.pone.0021766. Epub 2011 Jul 21.

4.

Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.

Brost S, Zimmermann A, Koschny R, Sykora J, Stremmel W, Schirmacher P, Walczak H, Ganten TM.

Pathol Res Pract. 2014 Feb;210(2):83-91. doi: 10.1016/j.prp.2013.10.005. Epub 2013 Nov 7.

PMID:
24268735
5.

Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity.

O'Leary L, van der Sloot AM, Reis CR, Deegan S, Ryan AE, Dhami SP, Murillo LS, Cool RH, Correa de Sampaio P, Thompson K, Murphy G, Quax WJ, Serrano L, Samali A, Szegezdi E.

Oncogene. 2016 Mar 10;35(10):1261-70. doi: 10.1038/onc.2015.180. Epub 2015 Jun 8.

PMID:
26050621
6.
7.

[Progress on targeting TRAIL's receptor as antitumor strategy].

Chen SZ.

Yao Xue Xue Bao. 2009 Dec;44(12):1336-42. Review. Chinese.

PMID:
21351465
8.

Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer.

Narayan G, Xie D, Ishdorj G, Scotto L, Mansukhani M, Pothuri B, Wright JD, Kaufmann AM, Schneider A, Arias-Pulido H, Murty VV.

Genes Chromosomes Cancer. 2016 Feb;55(2):177-89. doi: 10.1002/gcc.22325. Epub 2015 Nov 6.

PMID:
26542757
9.

TRAIL gene expression analysis in multiple sclerosis patients.

Taheri M, Nemati S, Movafagh A, Saberi M, Mirfakhraie R, Eftekharian MM, Arsang-Jang S, Rezagholizadeh A, Sayad A.

Hum Antibodies. 2016 May 20;24(1-2):33-8. doi: 10.3233/HAB-160291.

PMID:
27472871
10.

The role of cell type-specific responses in IFN-β therapy of multiple sclerosis.

Zula JA, Green HC, Ransohoff RM, Rudick RA, Stark GR, van Boxel-Dezaire AH.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19689-94. doi: 10.1073/pnas.1117347108. Epub 2011 Nov 21.

11.

Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors.

Hu L, Cao D, Li Y, He Y, Guo K.

Cancer Biol Ther. 2012 May;13(7):516-26. doi: 10.4161/cbt.19601. Epub 2012 May 1.

PMID:
22406996
12.

TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis.

Wandinger KP, Lünemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A, Grundström E, Ehrlich S, Wernecke KD, Volk HD, Zipp F.

Lancet. 2003 Jun 14;361(9374):2036-43.

PMID:
12814715
13.

Brief Report: Autocrine Cytokine-Mediated Deficiency of TRAIL-Induced Monocyte Apoptosis in Rheumatoid Arthritis.

Meusch U, Klingner M, Mathar C, Malysheva O, Baerwald C, Rossol M, Wagner U.

Arthritis Rheumatol. 2015 Jul;67(7):1760-5. doi: 10.1002/art.39138.

14.
15.

TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis.

Singh HD, Otano I, Rombouts K, Singh KP, Peppa D, Gill US, Böttcher K, Kennedy PTF, Oben J, Pinzani M, Walczak H, Fusai G, Rosenberg WMC, Maini MK.

Sci Rep. 2017 Jul 17;7(1):5514. doi: 10.1038/s41598-017-05845-5.

16.

Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.

Morizot A, Mérino D, Lalaoui N, Jacquemin G, Granci V, Iessi E, Lanneau D, Bouyer F, Solary E, Chauffert B, Saas P, Garrido C, Micheau O.

Cell Death Differ. 2011 Apr;18(4):700-11. doi: 10.1038/cdd.2010.144. Epub 2010 Nov 12.

17.

Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells.

Wendling U, Walczak H, Dörr J, Jaboci C, Weller M, Krammer PH, Zipp F.

Cell Death Differ. 2000 Jul;7(7):637-44.

18.

Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils.

Kamohara H, Matsuyama W, Shimozato O, Abe K, Galligan C, Hashimoto S, Matsushima K, Yoshimura T.

Immunology. 2004 Feb;111(2):186-94.

19.

High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.

Chamuleau ME, Ossenkoppele GJ, van Rhenen A, van Dreunen L, Jirka SM, Zevenbergen A, Schuurhuis GJ, van de Loosdrecht AA.

Leuk Res. 2011 Jun;35(6):741-9. doi: 10.1016/j.leukres.2010.12.032. Epub 2011 Feb 1.

20.

Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.

Gómez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J.

Exp Cell Res. 2007 Jul 1;313(11):2378-88. Epub 2007 Mar 30.

PMID:
17462628

Supplemental Content

Support Center